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1. Introduction
Neonatal cholestasis is one of the commonest presentations in the field of pediatric hepatol‐
ogy and gastroenterology and constitutes the major indication for liver transplantation be‐
low two years of age. Unfortunately, in spite of being common, fewer categories are
amenable to curative or palliative therapy. Moreover, delayed referral to specialized centers
is still a problem adding a more difficulty to neonatal cholestasis management. Hepatobili‐
ary surgery is a major line of therapy in some etiologies of neonatal cholestasis. Biliary atre‐
sia, choledochal cyst, spontaneous perforation of the bile duct and inspissated bile
syndrome are among the commonest known causes for hepatobiliary surgeons. However,
there is less orientation about other causes, resulting in progression to cirrhosis and end
stage liver disease without being diagnosed. One of these is the progressive familial intrahe‐
patic cholestasis (PFIC) group of diseases [1].
PFIC is an autosomal recessive liver disorder characterized by an intrahepatic cholestasis
due  to  bile  canalicular  transport  defects.  It  is  subdivided into  three  types  with  slightly
different clinical,  biochemical and histological features. PFIC types 1, 2 and 3 are due to
mutations  in  ATP8B1  (adenosine  triphosphatase,  type  8B,  member  1),  ABCB11  (adeno‐
sine  triphosphate-binding cassette,  subfamily  B,  member  11)  and ABCB4  (adenosine  tri‐
phosphate-binding  cassette,  subfamily  B,  member  4)  genes,  respectively.  Each  of  these
genes encodes a hepatocanalicular transporter which is essential for the proper secretion
and formation of bile [2].
PFIC1 and PFIC2 usually appear in the first months of life, whereas onset of PFIC3 may also oc‐
cur later in infancy, in childhood or even during young adulthood. The shared main clinical
manifestations in all types are cholestasis and pruritus. PFIC represents 10-15 % of causes of
cholestasis in children and 10-15% of indications of liver transplantations in children [3].
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In this chapter, we want to highlight the etiology, pathophysiology, clinical presentation and
the role of surgery in the management of this disease category, especially that medical thera‐
py is of limited value in a magnitude of cases. Moreover, liver transplant is not without sig‐
nificant side effects. So, raising the orientation about this not uncommon condition will help
in timely surgical intervention and improving patients' outcome.
2. Historical background
This disorder was first described by Clayton in 1965, and was termed Byler’s disease after an
American Amish kindred in which it was discovered [4]. Clinical features included severe pru‐
ritus, steatorrhea, poor growth and progression to cirrhosis in early childhood. A prominent
finding was a low or normal serum gamma glutamyl transpeptidase (GGT), which was dis‐
cordant with the severe cholestasis. Since its discovery, similar clinical features were described
in non-Amish children. Therefore, the more descriptive term, PFIC, is preferred [5].
However, this PFIC nomenclature is not always entirely satisfactory. A preferable term is
“bile canalicular transport disorders,” especially as it has become apparent that these genetic
disorders have numerous clinical phenotypes across all age brackets. For example, benign
recurrent intrahepatic cholestasis (BRIC) and intrahepatic cholestasis of pregnancy (ICP) can
occur in association with abnormalities in any of the three affected genes [2,6]. However, the
PFIC nomenclature is still in use due to its popularity in the literature.
Benign recurrent intrahepatic cholestasis, first described in 1959, is an intermittent form of
intrahepatic cholestasis characterized by variable periods of intense pruritus often associat‐
ed with jaundice [7]. The age of onset is variable, but it typically occurs during childhood or
adolescence. The severity and duration of attacks also vary and triggering features are not
well known. The benign designation of BRIC refers to the general lack of progressive liver
disease, although the pruritus is far from benign during an intense episode [8-10].
As the clinical spectrum between BRIC and PFIC (formerly named Byler’s disease) may be a
continuum, thus the historical nomenclature of Byler’s disease and BRIC may be outdated
[11]. So, many clinicians now refer to all these diseases in a general sense as ATP8B1,
ABCB11 and ABCB4 deficiency diseases to express the wide continuum of disease severity
between the PFIC and BRIC phenotypes [2].
3. Etiology and pathophysiology
3.1. PFIC 1 (ATP8B1 "FIC-1" deficiency)
PFIC1 is an autosomal recessive disease caused by mutations in ATP8B1 (formerly named
FIC1) gene on chromosome 18, locus q21-22. This gene encodes a transporter localized on the
canalicular membrane of hepatocytes (Figure 1), named FIC1 (ATP8B1), a P-type ATPase [12].
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Abbreviations: FIC1: familial intrahepatic cholestasis 1; BSEP: bile salt export pump; MDR3: multidrug resistence pro‐
tein 3.
Figure 1. A schematic representation of the hepatocyte with its canalicular membrane transporters involved in bile
formation. FIC1 is an aminophospholipid flippase, encoded by the ATP8B1 (FIC1) gene. BSEP (bile salt export pump)
(formerly sister of P-glycoprotein "SPGP") is a bile acids transporter to the bile canalicular lumen against a high concen‐
tration gradient. It is encoded by the ABCB11 (BSEP) gene. The MDR3 is a phospholipid transporter. It is encoded by the
ABCB4 (MDR3) gene.
The most widely accepted hypothesis for FIC1 function is that of an aminophospholipid
flippase, translocating phospholipids such as phosphatidylserine from the outer to the inner
leaflet of the plasma membrane [13]. So, deficiency of FIC1 in the hepatocyte results in the
loss of asymmetric distribution of phospholipids in the canalicular membrane, decreasing
both membrane stability and function of transmembrane transporters including the bile salt
export pump (BSEP) and, as such, causing bile salt retention in hepatocytes with consequent
defective bile formation; resulting in cholestasis [14-16].
Different studies have shown that ATP8B1 deficiency is associated with diminished FXR
(farnesoid X receptor) activity. The FXR is a nuclear receptor that is highly expressed in the
liver and regulates bile acid homeostasis so as to reduce its hepatocyte toxicity. Diminished
FXR activity leads to upregulation of bile acid synthesis, reduced expression of the canalicu‐
lar BSEP, and increased expression of the ileal apical sodium dependent bile acid transport‐
er (ASBT). The net effect of these changes would be increased synthesis of bile acids and
diminished its canalicular excretion, coupled with enhanced reabsorption of intestinal bile
acids, yielding marked hepatocyte bile acid overload [17,18].
ATP8B1 is abundantly expressed in a wide variety of tissues such as the small intestine,
bladder and stomach and to a lesser extent also in the liver and pancreas. This results in the
multitude of the extrahepatic manifestations such as the hearing loss, pancreatitis and diar‐
rhea, found in patients with ATP8B1 deficiency [19,20]. Over 50 distinct mutations in
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ATP8B1 are described. The mutations G308V found in Amish, D554N found in Inuits and
I661T are amongst the most frequently detected [21,22].
In vitro studies showed that ATP8B1 deficiency due to common missense mutations such as
G308V, D554N and I661T, can be regarded as a protein folding disease, with different de‐
grees of retention of the mutant protein in the endoplasmic reticulum, resulting in a de‐
creased protein expression at the plasma membrane [23]. The pathophysiologic concept of
being a protein folding disease can be used in new therapeutic interventions [24]. Incubation
at a reduced temperature could improve proper folding of some of the mutated proteins.
Similarly, the pharmacological chaperone 4-phenylbutyrate acid (4-PBA) could stabilize
misfolded proteins, partially restoring cell surface expression [25].
Mutations in ATP8B1 are also responsible for:
1. Greenland Eskimo cholestasis (Nielsen syndrome) [26].
2. Benign recurrent intrahepatic cholestasis-1 (BRIC1) [12].
3. Intrahepatic cholestasis of pregnancy-1 (ICP1) [27].
4. Down regulation of CFTR (cystic fibrosis transmembrane regulator): ATP8B1 is highly
expressed in biliary epithelial cells, and when it is abnormal in PFIC1, CFTR down reg‐
ulation in cholangiocytes has been reported which could contribute to impairment of
bile secretion [28].
3.2. PFIC 2 (ABCB11 "BSEP" deficiency)
PFIC2 is an autosomal recessive disease caused by mutations in the ABCB11 (formerly
named BSEP) gene encoding the BSEP, a liver-specific adenosine triphosphate (ATP)-bind‐
ing cassette transporter formerly known as sister of P-glycoprotein (SPGP). BSEP is located
in the hepatocyte canalicular membrane (Figure 1). ABCB11 gene is located on chromosome
2, locus q24 [29-31].
The defective canalicular BSEP expression leads to markedly diminished bile salt secretion.
This leads to bile secretory failure with secondary retention of bile salts and other biliary con‐
stituents in the hepatocytes leading to progressive liver damage and progressive cholestasis.
BSEP deficiency represents also a phenotypic continuum between BRIC2 and PFIC2. Different
mutations may cause different kinds of BSEP dysfunction, including protein lack, misfolded
protein, or protein not delivered from the Golgi to the bile canalicular membrane [31].
Generally missense mutations, e.g. E297G or D482G, lead to a less severe phenotype than mu‐
tations that are predicted to result in premature protein truncation or total failure of protein
production [31,32]. In vitro, the residual transport function of mutant proteins correlates with
the phenotypic differences between BRIC2 and PFIC2, with generally a diminished function in
BRIC2 mutants, while complete abolishment is more often seen in PFIC2 mutants [33].
Heterozygous ABCB11 mutations have also been identified in cases of ICP (ICP2) [34], drug
induced cholestasis [35] and transient neonatal cholestasis [36].
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3.3. PFIC 3 (ABCB4 "MDR3" deficiency)
PFIC3 is an autosomal recessive disorder due to mutations in the ABCB4 (formerly named
MDR3) gene located on chromosome 7, locus q21, which codes for the class III multidrug
resistance P-glycoprotein (MDR3). MDR3 is located exclusively on the canalicular mem‐
brane of the hepatocyte and serves as a phospholipid translocator (Figure 1) essential for
biliary phospholipid (e.g. phosphatidylcholine "PC") secretion [37].
PC in bile normally protects cholangiocytes from bile salt toxicity by forming mixed micelles
with it. However, a mutation of the ABCB4 gene results in decreased biliary PC secretion
and high biliary bile salt -to-PC ratio, leading to bile duct injury (cholangitis and ductular
proliferation). Also, a decreased biliary PC concentration leads to high biliary cholesterol -
to-PC ratio. The high biliary cholesterol saturation promotes crystallization of cholesterol
and the lithogenicity of bile [2,38].
Whereas biliary bile salt concentrations are normal in patients with PFIC3, serum bile salt
levels are elevated. It is explained by:
1. Downregulation of the bile acid importers to the hepatocyte, NTCP (Na+/taurocholate
cotransporting polypeptide) and OATP (organic acid transporting polypeptide) [39].
2. Upregulation of the bile acid exporter from hepatocyte at the sinusoidal membrane, MRP4
(multidrug resistance–related protein 4), mediating bile salt efflux into serum [40].
Over 45 disease-causing mutations in ABCB4 have been identified [41]. Children with mis‐
sense mutations seem to have a less severe phenotype, with later onset of disease, slower
progression and better response to treatment, as compared to patients with mutations lead‐
ing to a truncated protein [42]. Possibly this is due to residual transport activity in MDR3
protein affected by missense mutations.
Heterozygous mutations in the ABCB4 gene can also cause or predispose for a variety of other
liver diseases, such as adult biliary cirrhosis, cholelithiasis, transient neonatal cholestasis, drug
induced cholestasis and ICP. Mutations can even lead to a cascade of several phenotypes in one
patient, indicating the wide phenotypical spectrum of ABCB4 deficiency [43,44].
A small proportion of PFIC phenotypes are not due to mutations in these three genes and
therefore additional genes might be involved [2,45].
4. Clinical picture
Mutations in ATP8B1 and ABCB11 can result both in progressive cholestatic disease termed
PFIC1 and PFIC2, as well as in episodic cholestasis, referred to as BRIC type 1 and 2 respec‐
tively. This suggests that PFIC and BRIC are the two ends of a clinical spectrum, with differ‐
ent degrees of severity in between. Therefore, these diseases are preferably referred to as
ATP8B1 deficiency and ABCB11 deficiency. While mutations in ABCB4 can result in pro‐
gressive cholestatic disease only designated PFIC type 3. Similarly PFIC3 is best designated
as ABCB4 deficiency. Heterozygous mutations in any of these three genes can also be associ‐
ated with ICP. It is a transient form of cholestasis, characterized by the onset of pruritus dur‐
ing pregnancy, with postnatal resolution [2].
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Pruritus is the prominent clinical feature of PFIC; however, until an episode of jaundice in‐
tervenes, the diagnosis is often overlooked. Even then, because of the rarity of the condition,
children sometimes receive a misdiagnosis of obstructive jaundice caused by the occasional‐
ly associated choledocholithiasis in PFIC types 2 and 3 [5].
4.1. PFIC1 "Byler's disease"
• Cholestasis is a major clinical sign in PFIC1 as in all PFIC forms. It usually appears in the
first months of life in patients with PFIC1, and is characterized by recurrent episodes of
jaundice, which become permanent later in the course of the disease [3]. The variable clin‐
ical features are:
1. Jaundice: It presents with conjugated hyperbilirubinemia in the first 3–6 months of life.
The degree of jaundice may vary [46].
2. Pruritus: It is the dominant feature in the majority of patients and is often out of propor‐
tion to the level of jaundice [46]. It may initially vary in intensity and may be exacerbat‐
ed during intercurrent illness. Pruritus may not be noticed until 6 months of age
because the neural pathways necessary for concerted scratching are not fully devel‐
oped. However, affected infants often are irritable and sleep poorly with onset of cho‐
lestasis. Scratching is usually evident first as digging at the ears and eyes, which are the
first areas to show evidence of excoriation. By one year of age, patients may show gen‐
eralized mutilation of skin, usually most severe on the extensor surfaces of the arms
and legs and on the flanks of the back. The pruritus is very disabling and often re‐
sponds poorly to medical therapies [12,45].
3. Hepatomegaly is present early in life and persists with progression to cirrhosis. The rate
of progression to cirrhosis is variable, but usually develops in early childhood without
treatment. With progression to cirrhosis splenomegaly develops.
4. Fat-soluble vitamin deficiencies, including rickets, may be severe.
5. Extrahepatic disorders [19]:
• Persistent diarrhea with fat malabsorption and protein loss, leading to poor growth
and short stature.
• Bouts of pancreatitis.
• Recurrent pneumonia may also compromise growth.
• Sensorineural hearing loss may occur.
• As it has been mentioned before, ATP8B1 deficiency can lead to a continuum of disease
severity ranging from the progressive form PFIC1 to the recurrent form, BRIC1. BRIC1
will be discussed briefly in the next paragraphs.
BRIC is an intermittent form of intrahepatic cholestasis characterized by variable periods
of intense pruritus often associated with jaundice, separated by symptom-free intervals.
The benign designation of BRIC refers to the general lack of progressive liver disease, al‐
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though the pruritus is far from benign during an intense episode [10]. Two types of BRIC
are present according to the gene defect. BRIC1 is due to a mutation of ATP8B1 gene and
BRIC2, due to ABCB11 gene mutations.
The age of presentation of the first attack of jaundice ranges from 1–50 years, but jaundice
usually occurs before the age of twenty years. Attacks usually are preceded by a minor
illness and consist of a preicteric phase of 2–4 weeks (characterized by malaise, anorexia,
and pruritus) and an icteric phase that may last from 1–18 months. In some patients, hor‐
monal factors such as the use of oral contraceptives and pregnancy have been associated
with precipitation of an attack [10,47]. Patients may have severe coughing during epi‐
sodes, as is seen sometimes in patients with PFIC1 [48].
During the icteric phase, the concentrations of serum bile acid, bilirubin, and alkaline
phosphatase (ALP) are increased. Serum GGT concentration, however, remains low. Liver
biopsy results are very benign, often showing no pathologic change even during an epi‐
sode. Some specimens show hepatocellular cholestasis and cholate injury, mostly centri‐
lobular. During the asymptomatic period, all parameters (clinical, laboratory and liver
histology) are normal [49].
4.2. PFIC2 "Byler's syndrome"
• PFIC2 affected children differ from those with PFIC1 in some important respects:
The initial presentation and the evolution seem to be more severe than PFIC1, with per‐
manent jaundice from the first months of life and rapid appearance of cirrhosis and liver
failure within the first years of life [3].
They do not have extrahepatic involvement such as pancreatitis or diarrhea [45].
Early hepatocellular carcinoma (before one year of age) may complicate the course of
PFIC2 [3]. Up to 15% of the patients with ABCB11 deficiency will develop hepatocellular
carcinoma (HCC) or cholangiocarcinoma. Close surveillance for hepatobiliary malignancy
is therefore warranted in these patients [31,32,45].
At diagnosis, the cholestasis in ABCB11 deficiency results in a more detectable fat-soluble
vitamin deficiency manifestations [45].
The development of cholelithiasis in approximately one third of the patients, probably
due to the low bile salt concentration in bile, secondary to impaired BSEP function, which
might cause supersaturation of cholesterol [32].
• Patients fitting the phenotype of BRIC have been described with mutations in ABCB11.
They are called BRIC2 and are characterized by:
The age of onset and total number of recurrent episodes were highly variable. Choleli‐
thiasis  occurred in  many patients  with  BRIC2.  Several  patients  had a  relatively  early
onset of the disease and developed permanent cholestasis as adults after initial periods
of recurrent attacks.
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Occasionally BRIC will progress to the more severe and permanent form of PFIC, indi‐
cative  of  a  clinical  continuum,  with  intermediate  phenotypes  between  mild  and pro‐
gressive disease [2,11].
4.3. PFIC3 "MDR3 deficiency"
Mutations in the ABCB4 gene can cause or predispose to a variety of liver diseases with dif‐
ferent age of presentation. Moreover, it can even lead to a cascade of several phenotypes in
one patient, indicating the wide phenotypical spectrum of ABCB4 deficiency [43].
1. PFIC3: it is characterized by:
• Cholestasis developing within the first year of life in about one third of patients and
rarely in the neonatal period. It may also manifest later in infancy, in childhood or
even in young adulthood [3,45].
• Pruritus occurs less frequently than in the other types of PFIC and is usually mild.
• Jaundice may be less prominent than pruritus.
• Height and weight may be below normal as the disease progresses.
• Hepatomegaly, and at later stages splenomegaly, as a manifestation of portal hyperten‐
sion is often observed. Liver disease tends to evolve slowly to biliary cirrhosis with
or without overt cholestatic jaundice [42,50].
• Cholelithiasis may develop in older children.
• No extrahepatic features or occurrence of malignancies are described in association
with PFIC3 [42,50].
2. Adult biliary cirrhosis: gastrointestinal bleeding due to portal hypertension and cirrhosis
may be the presenting symptom in adolescent or young adult patients [3].
3. ICP: some cases of ICP have been associated with heterozygous mutations in ABCB4 [43].
4. Heterozygous mutations in the ABCB4 gene can also cause or predispose for transient
neonatal cholestasis and drug induced cholestasis [44].
5. Diagnosis
Diagnosis is dependent firstly on suspicion. The most alarming point making PFIC in the
scope of diagnosis is the presence of significant pruritus out of proportion to the level of
jaundice especially in the setting of low GGT. However, accurate diagnosis is dependent on
a constellation of a clinical, biochemical, radiological, histopathological, immunohistochemi‐
cal studies and finally can be confirmed by genetic testing for mutations (Table 1).
1. Biochemical parameters:
Hepatic Surgery570
• Serum GGT is repeatedly normal or low in PFIC1 & PFIC2, while it is elevated in
PFIC3 often more than ten times the normal value. In PFIC1 and PFIC2, the serum
GGT concentration may increase to greater than 100 IU/L in patients receiving micro‐
somal inducers such as phenobarbital and rifampicin [51].
The mechanism for the low serum concentration of GGT in PFIC1 and 2 is not clear.
GGT is normally bound to the canalicular membrane by a glycosyl phosphatidyl inosi‐
tol (GPI) anchor. In obstructive cholestasis, when excessive amounts of bile salts accu‐
mulate in the canalicular lumen under increased pressure, GGT is released from the
membrane by detergent action and refluxes back into serum, possibly via leaky inter‐
cellular junctions. However, in PFIC and BRIC types 1 and 2, the reduced concentra‐
tions of biliary bile acids preserve canalicular GGT localization. This explanation is not
entirely satisfactory as serum GGT is elevated in most other forms of intrahepatic cho‐
lestasis in which biliary bile acid levels are low. Preliminary studies indicate that some
canalicular proteins, including GGT and carcinoembryonic antigen (CEA), are poorly
expressed at the canaliculus in PFIC1 and 2. It is possible that low serum GGT levels re‐
sult from the lack of canalicular GGT available for elution as well as from the inade‐
quate concentrations of intracanalicular bile acids to act as detergents [51,52].
• Serum transaminases: In PFIC1 serum transaminases are mildly elevated. While in pa‐
tients with PFIC2, serum transaminases levels are usually elevated to at least five
times normal values. In PFIC3, serum aminotransferases, conjugated bilirubin, and
ALP are all significantly elevated [2,45].
• Serum cholesterol: it is characteristically low or normal in all the three types [3].
• Serum bile acid concentration: it is elevated in all the three types [44,45].
• Alpha-fetoprotein: it is elevated at diagnosis in PFIC2 than that in PFIC1 [12,45].
• Absent serum lipoprotein X (LPX) in PFIC3: because measurement of biliary phospholi‐
pids is impractical in the evaluation of most patients, measurement of serum LPX
may serve as a surrogate marker for PFIC3. LPX is the predominant lipoprotein in
the plasma of cholestatic patients. LPX is absent from the serum of patients with ho‐
mozygous ABCB4 mutations. LPX is probably composed of biliary vesicles that are
formed at the subapical compartment of the hepatocyte, transcytosed to sinusoidal
membrane, and released into plasma. This process is absolutely dependent on MDR3,
but the precise mechanism has not been defined [50,53].
2. Biliary bile analysis:
Biliary bile analysis is performed on gallbladder bile or on bile collected by duodenal aspira‐
tion (pure choledochal bile). In case of gallbladder punction, bile contamination by blood
may falsify bile analysis. In case of duodenal aspiration, bile dilution or bile contamination
by alimentary phospholipids may falsify bile analysis [3].
The biliary bile salt concentration is dramatically decreased (<1 mmol/L) in PFIC2 patients [54]
and only mildly decreased in PFIC1 patients (3–8 mmol/L) [19]. The normal concentration of
biliary primary bile salts distinguishes PFIC3 patients from those with PFIC1 and PFIC2 [42].
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In PFIC3 patients, the cardinal feature is the dramatically decreased biliary phospholipid
level  (1–15% of  total  biliary lipids;  normal  range 19–24%).  Biliary bile  salt-to-phospholi‐
pid is approximately 5-fold higher than in wild type bile, as is also biliary cholesterol-to-
phospholipid [3].
3. Radiological:
Initial ultrasonography of the liver is performed to exclude biliary tract disease. Typically,
ultrasonography is normal but may reveal a huge gallbladder in PFIC3. Sometimes, biliary
stones may be identified in both PFIC2 and PFIC3 [3].
Cholangiography performed in a limited number of  patients  with PFIC3 showed a nor‐
mal biliary tree, excluding sclerosing cholangitis, and allowed bile to be collected for bili‐
ary lipid analysis [42].
4. Histopathology: Liver biopsy shows:
• In PFIC1
Light microscopy (LM): on routine hematoxylin and eosin (H & E) staining, liver biopsy
shows bland cholestasis with almost no inflammation. It shows canalicular bile plugs of
distinctive color. Small-duct paucity may be present. Fibrosis starts early, with approxi‐
mately 75 % of patients having some fibrosis by 2 years of age. Fibrosis may appear ini‐
tially either as pericentral sclerosis or portal fibrosis, or sometimes both. Portal to
central bridging then develops in association with lacy lobular fibrosis and eventually
leads to cirrhosis. Proliferating bile ductules are observed at the edge of the portal tracts
in patients with significant fibrosis. The rate of progression of the fibrosis is highly vari‐
able but correlates loosely with the severity of the clinical disease [45].
On electron microscopy (EM), canalicular bile plugs shows characteristic granular
appearance “chunky bile”.
• In PFIC2
LM: on H & E stains, there is inflammation with giant cell hepatitis, fibrosis and duct
reaction [45].
On EM, bile appears amorphous [45].
• In PFIC3
LM: on H & E stains, bile ductular proliferation and mixed inflammatory infiltrates
are  observed  in  the  early  stages  despite  patency  of  intra-  and  extrahepatic  bile
ducts. Cholestasis with slight giant cell transformation and isolated eosinophilic ne‐
crotic hepatocytes may also be present. Periductal sclerosis affecting the interlobu‐
lar  bile  ducts  eventually  occurs.  Extensive  portal  fibrosis  evolves  into  biliary
cirrhosis in older children [42].
EM of liver has not been reported in proven cases.
5. Immunohistochemical staining:
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Commercially available MDR3 and BSEP antibodies allow liver immunostaining to be per‐
formed. Absence of canalicular or mild immunostaining is in favor of a gene defect. Howev‐
er, normal staining does not exclude a gene defect as a mutation may induce a loss of
function but normal synthesis [31,42].
6. Genetic testing:
Molecular analysis remains the definitive diagnostic technique for PFIC. Gene analysis is
usually performed by DNA sequencing of the 27 coding exons (coding exons 2-28) of the
ATP8B1, ABCB11, and ABCB4 genes and their splice junctions [3]. The use of a resequensing
chip dedicated to genetic cholestasis could facilitate identification of gene mutation [55].
 PFIC-1 PFIC-2 PFIC-3 
Synonyms Byler disease 
ATP8B1 deficiency  
FIC1 deficiency 
Byler syndrome  
ABCB11 deficiency  
BSEP deficiency 
ABCB4 deficiency  
MDR3 deficiency  
Gene defect ATP8B1 (FIC1) ABCB11 (BSEP) ABCB4 (MDR3) 
Locus 18q21-22 2q24 7q21 
Transport defect Aminophospholipid Bile acid Phospholipids    
Pathophysiology Impaired inward 
translocation of 
aminophospholipids 
over cellular 
membranes 
Impaired canalicular 
bile salt transport 
secondary  to 
malfunction of BSEP 
Impaired canalicular 
translocation of 
phosphatidylcholine  
Clinical picture:    
Onset of cholestasis Neonatal Neonatal  Variable  
Pruritus  Severe Severe Moderate 
Extrahepatic 
manifestations 
Present 
 
Absent 
 
Absent 
 
Cholelithiasis  Absent Increased incidence  Increased incidence  
HCC No Risk from the 1st year No 
Clinical spectrum of 
gene defect 
PFIC1, BRIC1, and ICP PFIC2, BRIC2, and ICP PFIC3, ICP, adult 
biliary cirrhosis, 
cholelithiasis, transient 
neonatal cholestasis, 
drug induced 
cholestasis 
Biochemical: 
 
 
 
 
 
 
 
GGT Normal or low Normal or low Elevated 
Transaminases Mildly elevated More elevated Elevated  
Bile acids Elevated More elevated Elevated 
Cholesterol Normal Normal Normal  
Alpha fetoprotein Not significantly 
elevated 
More elevated -- 
Histopathological Bland cholestasis (LM) 
Coarse granular bile (EM
Giant cell hepatitis 
(LM) 
Amorphous bile (EM) 
Ductular proliferation 
(LM) 
Immunohistochemical -- Absent or reduced 
BSEP staining in the 
majority of patients 
Absent or reduced 
MDR3 staining in 
about 50 % of patients 
Table 1. Summary of the criteria of different PFIC types.
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6. Differential diagnosis
Two groups of diseases are in differential diagnosis with PFIC group of disorders. For
PFIC1 and PFIC2, it is to be differentiated from other cholestatic disorders with low GGT.
While for PFIC3, when it presents early it, is to be differentiated from cholestatic disorders
with high GGT and when it presents in an older age, childhood or adolescence, it is to be
differentiated from other causes of chronic liver diseases at respective ages.
• Cholestasis with low GGT:
1. Inborn errors of bile acid metabolism [6].
2. Familial hypercholanemia: familial hypercholanemia represents a PFIC-like disorder
due to a bile canalicular tight junction protein defect combined with a defect of pri‐
mary bile acid conjugation. Cholestasis is due to impaired transport of unconjugated
bile acids into bile and to bile leakage into plasma through abnormal canalicular tight
junctions increasing paracellular permeability [56].
3. Arthrogryposis-  renal  dysfunction  cholestasis  (ARC)  syndrome is  a  complex  dis‐
ease due to mutation of VPS33B  involved in intracellular trafficking and targeting
of apical proteins. The gene defect results in a loss of apical protein expression in
the liver and kidneys [57].
• Cholestasis with high GGT:
1. Biliary atresia [58].
2. Neonatal sclerosing cholangitis [59].
3. Congenital cytomegalovirus (CMV) infection.
4. Alpha1-antitrypsin deficiency disease [60].
5. North American Indian Childhood Cirrhosis (NAIC) [61].
6. Aagenaes syndrome (hereditary cholestasis with lymphedema): a very rare familial
cholestatic disorder with cholestasis and lower limb edema [62].
• Causes of chronic liver disease:
1. Chronic viral hepatitis.
2. Autoimmune  liver  diseases:  autoimmune  hepatitis  and  autoimmune  sclerosing
cholangitis.
3. Metabolic liver disorders, e.g., Wilson disease and alpha1-antitrypsin deficiency.
7. Treatment
Initial treatment of PFIC includes the use of cholestyramine, ursodeoxycholic acid, rifampi‐
cin, and phenobarbital [63-65]. Until the late 1980s, liver transplantation was the only effec‐
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tive therapy for those who did not respond to medical treatment [66,67]. Later on, less
invasive non-transplant surgical approaches were proposed and undertaken early in the
course of the disease with promising initial results [68]. In this section, a brief overview
about the different lines of management for PFIC patients will be given.
7.1. Medical therapy
Unfortunately, most forms of medical therapy for PFIC types 1, 2, and 3 are of limited effec‐
tiveness. Nevertheless, several treatment modalities can be used in specific patients to im‐
prove quality of life or prevent progression of the disease [2,69].
• Cholestyramine is an anion-exchange resin that binds bile salts, preventing their re-absorp‐
tion in the enterohepatic circulation. In PFIC, relief of pruritus and normalization of bio‐
chemical parameters is only described rarely with cholestyramine. However, in patients
with BRIC it can be helpful in shortening episodes [2].
• Rifampicin, although it accelerates the hepatic detoxification and excretion of compounds,
such as bilirubin and bile salts, it has been used with limited efficacy in patients with
PFIC [51]. Nevertheless, in patients with BRIC it can completely abort an episode.
• Ursodeoxycholic acid (UDCA) is a relatively hydrophilic bile salt, which is less cytotoxic
than endogenous bile salts. Upon oral administration (20 mg/kg/day), it will partially re‐
place endogenous bile salts in the bile salt pool, reducing injury of the hepatocytes during
cholestasis. In PFIC3 regular administration of UDCA normalizes liver function tests and
improves clinical parameters in up to 50% of the patients. The therapeutic effect appears
to be dependent on the type of mutation, with premature stop codons leading to a trun‐
cated protein being associated with nearly no response to therapy. UDCA should there‐
fore be the first choice in the initial therapeutic management of patients with ABCB4
deficiency, especially when a missense mutation in the corresponding gene is found [42].
In patients with PFIC1 or PFIC2, the results of UDCA treatment are conflicting, ranging
from clear improvement to no effect at all.
In this respect, the recommended treatment strategy is to start with UDCA therapy in all
types  of  PFIC,  especially  PFIC3.  If  no  appropriate  response,  especially  regarding  pruri‐
tus,  add the  other  medical  lines  of  therapy.  Those  who will  not  respond are  shifted to
surgical treatment [3,45,65,66].
7.2. Surgical treatment
Surgical treatment for PFIC is an important major line of therapy. If no complete clinical or
biochemical improvement is obtained with medical therapy, more invasive therapy such as
biliary diversion or even liver transplantation is necessary [2,70].
Interruption of the enterohepatic circulation through biliary diversion has yielded excellent
clinical, biochemical, and histologic response in a number of children with PFIC, provided the
procedure is performed before the development of significant hepatic fibrosis [46]. It reduces
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the accumulation of toxic bile salts by decreasing their intestinal re-uptake. It is unclear if these
approaches are optimal for specific genetic forms of PFIC rather than others. It is possible that
these interventions may be best for severe PFIC1 and milder phenotypic variants of PFIC2. Na‐
sobiliary drainage may help to select potential responders to biliary diversion [71].
There are three major non-transplant surgical techniques to permanently interrupt the enter‐
ohepatic circulation, namely partial external biliary diversion (PEBD), ileal bypass (IB) and
partial internal biliary diversion (PIBD).
• Partial external biliary diversion (PEBD):
PEBD interrupts the enterohepatic circulation of bile salts by partially diverting bile from the
gallbladder through a loop of jejunum connecting the gallbladder to the abdominal skin [72].
In 1988, Whitington and Whitington [68] introduced cholecystojejunocutaneostomy as a
PEBD for the surgical treatment of PFIC, to increase the elimination of bile acids accumulat‐
ed within the body and thus control the intractable pruritus. In this procedure, one end of a
loop of jejunum is anastamosed to the dome of the gallbladder, whereas the other is used to
form a cutaneous ostomy (Figure 2A). Bile in the gallbladder then flows either out of the os‐
tomy or into the intestine. Typically 30–50% of bile drains out of the ostomy and is discard‐
ed. Two variants on the original PEBD have also been described; one using a laparoscopic
technique [73] and the other using an appendiceal conduit [74].
Results of PEBD are promising with respect to pruritus, jaundice and histology, both in pa‐
tients with PFIC1 and PFIC2, with at least partial improvement in more than 75% of the pa‐
tients [66,72]. Although this seems promising, at present it is unclear whether in patients
responding to PEBD liver transplantation can also be avoided at long-term follow-up [75].
Moreover, some patients do not benefit from biliary surgery at all. Obviously in these pa‐
tients liver transplantation should be considered [72].
The type of mutation seems to be associated with the outcome of PEBD, with better progno‐
sis in disease caused by milder mutations, especially for the ABCB11 mutations E297G and
D482G [32,45]. However, when severe fibrosis is already present at the moment of PEBD,
prognosis is worse [72]. One patient with PFIC3 who underwent PEBD was described in lit‐
erature; this patient showed no improvement [67].
No serious PEBD complications are reported, although problems with the stoma (stenosis,
recurrent  bleeding) (Figure 2)  sometimes make a re-operation necessary.  In addition ex‐
cessive stomal losses can cause dehydration and electrolyte imbalance,  while cholangitis
can also develop [72,75].
The permanent character of the PEBD makes it less suitable for patients with episodic cho‐
lestasis (BRIC). In these patients temporary nasobiliary drainage (NBD) to interrupt the en‐
terohepatic circulation can be endoscopically introduced. This procedure is effective in most
of these patients, resolving pruritus and normalising bile salts within short time [10,71].
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Figure 2. A seven years old child diagnosed as PFIC2 underwent PEBD at the age of 2 years old with good outcome.
He had recurrent bleeding from the osteal opening (a). Endoscopy through the osteal opening (b) showed free jejunal
loop (c) till its proximal end at the gall bladder (d). The source of bleeding was the stoma itself.
• Terminal ileal exclusion or ileal bypass (IB):
Although most of PFIC patients and their parents tolerate well PEBD with its external bili‐
ary fistula and the need for stoma care, sometimes it becomes a real problem, particularly
for children of school age and teenagers, who may feel uncomfortable to participate in all
activities with their friends. Moreover, there is still a group of patients who cannot undergo
PEBD because of a previous cholecystectomy, or who develop postoperative electrolyte in‐
balance due to the excessive daily amount of bile [5,76].
To deal with these problems, an IB technique was proposed. In IB, the terminal ileum is
skipped by an ileocolonic anastomosis. It was developed as an alternative treatment to
PEBD, that avoids a long-term stoma complications. In 1994, Whitington et al. described a
good initial outcome of IB in two patients after cholecystectomy, but a chronic diarrhea oc‐
curred one year later. In 1998, Holland et al. described this procedure in PFIC children after
cholecystectomy. All patients were supplemented with vitamin B12 and folic acid. Interest‐
ingly, no diarrhea was reported postoperatively. Early results were very promising, with a
relief of pruritus and normalization of bilirubin level. Nevertheless, relapse of cholestatsis
occurred in half of the patients. The authors underline that IB is not as effective as PEBD and
therefore it should not be considered as the primary treatment in children with PFIC [5,51].
The rational of this technique was that the vast majority of intestinal bile salts are reabsor‐
bed in the distal ileum; that is the distal 15% of the small intestine. Therefore, exclusion of
this segment of intestine may lead to bile acid wasting. The small intestine is transected at a
point that demarcates the distal 15% of the small intestine, and a blind loop is formed with
the distal ileal segment. The proximal loop of the intestine is sewn end-to-side to the cecum,
completing the internal bypass of the distal ileum. Accurate assessment of the appropriate
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amount of ileum for bypass is likely to be critical; too little is unlikely to be therapeutic and
too much is likely to yield bile acid–induced diarrhea. Mutational analysis may be used
eventually to predict which patients are most likely to benefit from surgery. After IB, symp‐
toms may recur within one year requiring conversion to PEBD [5,77].
• Partial internal biliary diversion (PIBD):
PIBD interrupts the enterohepatic circulation of bile salts by partially diverting bile from the
gallbladder through a loop of jejunum connecting the gallbladder to the colon [46,76].
This operation combines the advantages of partially diverting the biliary flow from the en‐
terohepatic cycle (such as the PEBD does), while at the same time avoiding an external bili‐
ary fistula. In addition, this operation lacks the potential for malabsorption that may result
from partially excluding the terminal ileum from the intestinal transit. There is, however, a
potential for choleretic diarrhea, which may result from large amounts of bile salts entering
the colon. Because of this, it was strongly emphasized that the conduit should be made at
least 15 cm long to create a certain resistance to the bile flow; it is believed that this stimu‐
lates a certain amount of bile to flow through the normal biliary tract to the duodenum. This
problem occurred in a transient way in a few of the patients and it can be controlled with
the use of cholestyramine for a limited span of time [46].
Through an upper midline abdominal incision, the gallbladder and the liver are evaluated.
An intestinal conduit is constructed using a 15- to 20-cm segment of midjejunum, which is
sutured initially to the gallbladder wall and then terminolaterally to the midportion of the
ascending colon. The distal end of the jejunum is slightly tapered in a way that the jejunum
could reach the colon in an isoperistaltic direction to prevent colonic contents from entering
the conduit. The clinical and laboratory results described for PIBD make it a very attractive
surgical option for the treatment of PFICs in children with a normal gallbladder. However,
long-term follow-up is necessary to evaluate late results and eventual complications associ‐
ated with this technique [46].
If  all  previously  described therapies  fails  in  controlling pruritus,  when there  is  an end-
stage PFIC liver disease, or when the disease is progressive despite treatment; orthotopic
liver transplantation (OLT) remains the only alternative [78-80].  Before the development
of liver transplantation, therapy for these patients was generally ineffective. With the ad‐
vent of liver transplantation, many PFIC patients were treated with this life-saving proce‐
dure  [70,78].  At  one  time,  PFIC  was  among  the  5  most  common  indications  for  liver
transplantation in children [81,82].
Although OLT is associated with serious surgical risks and lifetime immunosuppressive
therapy is necessary, it usually gives complete correction of phenotype in patients with
PFIC2 and PFIC3 deficiency in which the disease is hepatocyte specific. However, phenotyp‐
ic recurrence of severe PFIC2 deficiency post-transplantation can occur as a result of the for‐
mation of autoantibodies against BSEP [83,84]. Intensifying immunosuppressive therapy
may resolve this problem.
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In contrast, in PFIC1, liver transplantation is potentially fraught with a number of potential
complications related to the extrahepatic expression of the ATP8B1 gene. The most promi‐
nent posttransplantation problems include intractable diarrhea, hepatic steatosis, poor
growth, and recurrent pancreatitis. Worsening diarrhea post liver transplant might be due
to an imbalance between bile salt excretion and re-absorption, since the hepatic graft ex‐
cretes a normal amount of bile salts, whereas the intestine remains functionally impaired.
The resulting increased amount of bile salts in the ileum and colon induces or worsens diar‐
rhea, which might respond to cholestyramine treatment [19,85]. Therefore, in PFIC1, non-
transplant surgical approaches should be considered the preferred first-line of therapy.
In summary, children with PFIC do better with non-transplant surgical interventions than
they do with the natural history of disease, which is uniformly fatal. Successful outcomes
have been demonstrated, with marked improvements in clinical symptoms, laboratory val‐
ues, growth and histology. It appears that the success rate is high enough that many patients
may do better with a non-transplant procedure than transplant given the posttransplant
morbidities associated with immunotherapy. Those with more advanced disease are most
likely to have a poor outcome with non-transplant surgical procedures. This may encourage
clinicians to consider a surgical intervention early in the course of disease before significant
hepatic scarring develops [76].
Some authors proposed that the treatment strategy is to perform PEBD rapidly after diagno‐
sis in patients with PFIC1 & PFIC2 and to consider OLT when treatment fails. In patients
with PFIC3, UDCA treatment is the first-line therapy; if not successful it is followed by liver
transplantation. In patients with episodic cholestasis (BRIC) medical treatment with rifampi‐
cin with or without cholestyramine can be attempted at the start of an attack. If medication
is not successful in aborting the cholestatic episode NBD can be performed [2,69]. In BRIC
patients who progress to a more permanent form of cholestasis, or in patients with very fre‐
quent or debilitating attacks, a biliary diversion can be considered [69].
7.3. New and future therapies
New and future therapies for PFIC patients include hepatocyte transplantation, the use of
nuclear receptor ligands, enhancing the expression of the mutated transporter protein by
employing chaperones and mutation specific therapy [2,69].
Hepatocyte transplantation has been successful in partially repopulating the liver, diminish‐
ing pathology in a mouse model of ABCB4 deficiency, but unfortunately not yet in patients
[86]. In ABCB11 deficiency it is doubtful whether hepatocyte transplantation is a good thera‐
peutic option since possible premalignant cells are left in place.
Certain nuclear receptors regulate bile formation. The key nuclear receptor in bile formation
is the bile salt sensor FXR. Activated FXR transactivates a number of genes, resulting in im‐
proved bile salt excretion and detoxification. Targeting FXR with synthetic ligands is ex‐
plored as a possible therapeutic option for cholestasis syndromes [87].
A pharmacological chaperone is defined as a small molecule that specifically binds to its tar‐
get protein and induces or promotes proper folding and trafficking of the protein [88]. Some
Progressive Familial Intrahepatic Cholestasis
http://dx.doi.org/10.5772/51769
579
researchers have investigated the usefulness of pharmacological chaperones for treatment of
diseases caused by folding-defective membrane proteins [24,89,90]. Pharmacological chaper‐
ones such as 4-phenylbutyrate acid (4-PBA) have been shown to stabilize proteins misfolded
due to missense mutations, thereby preventing degradation in the endoplasmic reticulum.
In vitro, 4-PBA enhances cell surface protein expression for some of the missense mutations
found in ATP8B1 deficiency and ABCB11 deficiency [25,91]. Misawa et al [24], showed that
bile acids do act as pharmacological chaperones of E297G BSEP. They also described the dis‐
covery and structural development of non-steroidal compounds with potent pharmacologi‐
cal chaperone activity for E297G BSEP.
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